Atlas Trials

Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy

Clinical trial NCT04652258 · TERMINATED

Trial details

NCT number
NCT04652258
Sponsor
University of Zurich
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Pyrexia
Start date
2021-02-01
Primary completion
2021-10-31
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.